US FDA Approves Brintellix for Treatment of MDD in Adults: Takeda, Lundbeck

Takeda Pharmaceutical and H. Lundbeck A/S of Denmark announced on October 1 that the US FDA has approved Brintellix (vortioxetine), which was developed jointly by the two companies, for the treatment of adults with major depressive disorder (MDD). The two...read more